Cipla
Biosimilar developer, India. 1 development product across 1 molecule: insulin glargine.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Insulin glargine | Cipla insulin glargine | · | · | · | · | · | Aug 2023 | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which Cipla is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Epoetin alfa and zeta | Cipla (INN only) | CDSCO | Cipla Limited | Nov 2021 | Not stated in the CDSCO list |
| Etanercept | Cipla (INN only) | CDSCO | Cipla Limited | Oct 2012 | Not stated in the CDSCO list |
| Insulin lispro | Cipla (INN only) | CDSCO | Cipla Limited | Sep 2021 | Not stated in the CDSCO list |
| Somatropin | Cipla (INN only) | CDSCO | Cipla Limited | Oct 2020 | Not stated in the CDSCO list |
Companies on the same molecules
Developers whose portfolios overlap most with Cipla, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOAug 2023Cipla (INN only), insulin glargine
Compare Cipla with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant